Casanova-Sandoval Juan, Miñana-Escrivà Gema, Bosch-Peligero Eduard, Muñoz-Camacho Juan Francisco, Fernández-Rodríguez Diego, Rivera Kristian, Fernández-Cisnal Agustín, Valcárcel-Paz Daniel, García-Guimarães Marcos
Servicio de Cardiología, Hospital Universitario Arnau de Vilanova, Grup de Fisiologia i Patologia Cardiaca, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, España Servicio de Cardiología, Hospital Universitario Arnau de Vilanova Grup de Fisiologia i Patologia Cardiaca Institut de Recerca Biomèdica de Lleida (IRBLleida Lleida España.
Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Universidad de Valencia, Valencia, España Servicio de Cardiología, Hospital Clínico Universitario de Valencia Instituto de Investigación Sanitaria (INCLIVA) Universidad de Valencia Valencia España.
REC Interv Cardiol. 2025 Feb 24;7(1):23-28. doi: 10.24875/RECIC.M24000484. eCollection 2025 Jan-Mar.
Ultrathin-strut stents (UTS) represent a significant advancement in percutaneous coronary intervention. This study aimed to evaluate the safety and short- to mid-term outcomes of stenting with the thinnest struts on the market (50 µm) using a biodegradable everolimus-eluting polymer (Evermine 50) in real-world patients with coronary artery disease.
A single-arm, multicenter, prospective study was conducted in real-world patients. A total of 161 patients with de novo lesions who received at least 1 UTS stent were enrolled. The primary safety endpoint was the occurrence of major adverse cardiovascular events, defined as cardiac death, target-vessel myocardial infarction, or the need for revascularization of the target lesion at 12 months. The incidence of stent thrombosis at 12 months was also analyzed.
The study included 161 patients with a mean age of 64 ± 14 years; 79% were male, 34% had diabetes, and 66% had hypertension. The most common indication for intervention was non-ST-segment elevation myocardial infarction (42%), followed by ST-segment elevation myocardial infarction (22%). The procedural success rate was 100%. At 12 months of follow-up, the incidence of MACE was 2.5%, and the definite stent thrombosis rate was 1.3%.
The use of the 50 µm UTS stent with a biodegradable everolimus-eluting polymer demonstrated a favorable safety profile and good clinical outcomes in unselected patients at 1 year of follow-up.
超薄支架（UTS）是经皮冠状动脉介入治疗的一项重大进展。本研究旨在评估在真实世界的冠心病患者中，使用市场上最薄的支架（50微米）及可生物降解的依维莫司洗脱聚合物（Evermine 50）进行支架置入术的安全性和短期至中期疗效。
对真实世界的患者进行了一项单臂、多中心、前瞻性研究。共纳入161例接受至少1枚UTS支架的新发病变患者。主要安全终点是主要不良心血管事件的发生，定义为心脏死亡、靶血管心肌梗死或12个月时靶病变血运重建的需求。还分析了12个月时支架血栓形成的发生率。
该研究纳入了161例患者，平均年龄为64±14岁；79%为男性，34%患有糖尿病，66%患有高血压。最常见的干预指征是非ST段抬高型心肌梗死（42%），其次是ST段抬高型心肌梗死（22%）。手术成功率为100%。随访12个月时，主要不良心血管事件的发生率为2.5%，明确的支架血栓形成率为1.3%。
在未选择的患者中，使用带有可生物降解依维莫司洗脱聚合物的50微米UTS支架在随访1年时显示出良好的安全性和临床疗效。
